ScripGilead Sciences division Kite is aiming for its bicistronic anti-CD19/CD20 CAR-T therapy KITE-363 to be able to both tamp down toxicity in patients with B-cell lymphomas and to prevent CD19-negative r
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Will Try Camurus’s FluidCrystal D
ScripData presented in two oral sessions at the American Society of Clinical Oncology on the PD-1 inhibitor Libtayo (cemiplimab-rwlc) and the BCMAxCD3-directed bispecific antibody linvoseltamab illustrate
ScripBristol Myers Squibb is following Merck & Co. and Pfizer by buying into the bispecific PD-L1xVEGF-targeting mechanism for cancer, announcing on June 2 that it will pay $1.5bn up front to BioNTech